Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2026 | $8.00 | Overweight → Equal Weight | Barclays |
| 2/27/2026 | $10.00 | Buy → Hold | Craig Hallum |
| 1/6/2026 | $13.00 | Market Perform → Outperform | Leerink Partners |
| 11/21/2025 | $10.00 | Buy | Rothschild & Co Redburn |
| 11/13/2025 | $9.00 | Market Perform | BMO Capital Markets |
| 9/29/2025 | $16.00 | Buy | Craig Hallum |
| 7/3/2025 | $16.00 | Equal-Weight | Morgan Stanley |
| 5/8/2025 | $14.00 | Equal Weight → Overweight | Barclays |
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
Barclays downgraded Certara from Overweight to Equal Weight and set a new price target of $8.00
Craig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00
Leerink Partners upgraded Certara from Market Perform to Outperform and set a new price target of $13.00
8-K - Certara, Inc. (0001827090) (Filer)
10-Q - Certara, Inc. (0001827090) (Filer)
8-K - Certara, Inc. (0001827090) (Filer)
4 - Certara, Inc. (0001827090) (Issuer)
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: RBC CM Global Healthcare ConferenceDate and Time: Tuesday, May 19 at 9:30 a.m. ET William Blair's 46th Annual Growth Stock ConferenceDate: Tuesday, June 2 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3 at 1:20 p.m. ET Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates me
RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A
Altasciences, a fully integrated drug development solution company, and Certara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences' Acceleration Platform, the integration of Certara's strategic drug development services and biosimu
RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quarter Highlights: Appointment of Jon Resnick as Chief Executive Officer and Member of the Board of Directors, effective January 1st, 2026.Revenue was $103.6 million, compared to $100.4 million i
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t
SC 13G - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)